Brain Tumor Clinical Trials

The Gerald J. Glasser Brain Tumor Center offers patients hope through a robust clinical trial research program. Researchers are working to discover the next generation of brain tumor treatments.

Phone: 908-522-5914
Brain Metastases
Genetic-Guided Treatment for Brain Metastases

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Learn more about this trial

For Patients With Locally Advanced or Metastatic Solid Tumors

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.
Learn more about this trial >


For Newly-Diagnosed Patients with Glioblastoma Multiform (GBM)

Phase IIb RESTORE Trial

This phase II trial examines whether increasing oxygen delivery to hypoxic glioblastoma tissue via NanO2 will boost the effectiveness of frontline treatment with both radiation therapy and chemotherapy. Learn more about this trial


Patients Newly Diagnosed H3 K27M-mutant Gliomas

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

 For patients with Recurrent or Progressive grade 3 or 4 gliomas with IDH1 Mutation

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

This multi-site, Phase 1/2a clinical trial is an open label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma or patients with progressed or recurrent Grade III glioma. 

For patients with H3-K27M-mutant and/or Midline Gliomas

Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-Mutant and/or Midline Gliomas

This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.

Inhibitor Drug Therapy for Progressive Meningiomas

Designed for patients with meningiomas that are growing, spreading or getting worse, this phase II trial studies the efficacy of inhibitor drugs that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Learn more about this trial